In several studies, high claudin specificity of anti‐claudin antibodies (Cldn1, Yoda et al., 2014; Cldn4, Silva et al., 2017; Cldn5, Hashimoto et al., 2017; and Cldn18.2, Singh et al., 2017) was used for cancer cell targeting. Here, CLDN1 is linked to cancer.